Strong safety data from NORSE THREE registration trial consistent with other trials for ONS-5010 and in prior published research ISELIN, N.J. , Oct. 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first

Suber Huang, MD, MBA, FASRS, will present safety data from Outlook Therapeutics’ NORSE THREE registration trial on Tuesday, October 12, 2021 ISELIN, N.J. , Oct. 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the

Outlook Therapeutics senior leadership team to provide a company overview and participate on industry panel on Thursday, October 7, 2021 ISELIN, N.J. , Oct. 05, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first

Full year data reinforce strong safety profile consistent with previous trials of ONS-5010 and with prior published data on ophthalmic bevacizumab Full data to be presented at American Academy of Ophthalmology’s Retina Subspecialty Meeting, RET13 - Section X: Late Breaking Developments, Part II on

Live fireside chat with C. Russell Trenary, President and CEO of Outlook Therapeutics on Tuesday, September 28 at 2:00 PM ET ISELIN, N.J. , Sept. 21, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved

ISELIN, N.J. , Sept. 13, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the presentation of safety data from

ISELIN, N.J. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C.

Reported positive, statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD) On track to submit new U.S.

Russell Trenary , President and Chief Executive Officer of Outlook Therapeutics , to participate in The Greatest Unmet Needs Facing Ophthalmology Today panel on Tuesday, August 17 th at 9:00 AM ET ISELIN, N.J. , Aug. 11, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

In NORSE TWO, ONS-5010 achieved statistically significant and clinically relevant primary (p = 0.0052) and key secondary (p = 0.0043) efficacy endpoints with 41% of subjects gaining at least 15 letters In NORSE TWO, ONS-5010 was safe and well tolerated Management to host conference call and webcast